
Nicola Pomella

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7194799/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Microglia promote glioblastoma via mTORâ€mediated immunosuppression of the tumour microenvironment. EMBO Journal, 2020, 39, e103790.	7.8	77
2	Common Carotid Artery Diameter, Blood Flow Velocity and Wave Intensity Responses at Rest and during Exercise in Young Healthy Humans: A Reproducibility Study. Ultrasound in Medicine and Biology, 2017, 43, 943-957.	1.5	26
3	Inositol treatment inhibits medulloblastoma through suppression of epigenetic-driven metabolic adaptation. Nature Communications, 2021, 12, 2148.	12.8	20
4	Polycomb-mediated repression of EphrinA5 promotes growth and invasion of glioblastoma. Oncogene, 2020, 39, 2523-2538.	5.9	18
5	Comparative epigenetic analysis of tumour initiating cells and syngeneic EPSC-derived neural stem cells in glioblastoma. Nature Communications, 2021, 12, 6130.	12.8	14
6	Combination of BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma. Neuro-Oncology, 2022, 24, 1273-1285.	1.2	8
7	c-MYC overexpression induces choroid plexus papillomas through a T-cell mediated inflammatory mechanism. Acta Neuropathologica Communications, 2019, 7, 95.	5.2	6
8	Deletion of LBR N-terminal domains recapitulates Pelger-Huet anomaly phenotypes in mouse without disrupting X chromosome inactivation. Communications Biology, 2021, 4, 478.	4.4	5
9	Elucidation of the BMI1 interactome identifies novel regulatory roles in glioblastoma. NAR Cancer, 2021, 3, zcab009.	3.1	4
10	Impact of varying diastolic pressure fitting technique for the reservoir-wave model on wave intensity analysis. Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine, 2020, 234, 1300-1311.	1.8	1
11	EMBR-10. INOSITOL TREATMENT INHIBITS MEDULLOBLASTOMA THROUGH SUPPRESSION OF EPIGENETIC-DRIVEN METABOLIC ADAPTATION. Neuro-Oncology, 2021, 23, i7-i7.	1.2	0
12	MEDB-23. Targeting epigenetic dysregulation in medulloblastoma with poor prognosis. Neuro-Oncology, 2022, 24, i109-i110.	1.2	0